Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Change in Accured Expenses (2016 - 2022)

Eledon Pharmaceuticals filings provide 5 years of Change in Accured Expenses readings, the most recent being -$960000.0 for Q4 2017.

  • On a quarterly basis, Change in Accured Expenses fell 727.45% to -$960000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$2.0 million, a 2912.31% decrease, with the full-year FY2022 number at $2.1 million, down 2.89% from a year prior.
  • Change in Accured Expenses hit -$960000.0 in Q4 2017 for Eledon Pharmaceuticals, up from -$1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.4 million in Q4 2015 to a low of -$1.2 million in Q1 2015.
  • Median Change in Accured Expenses over the past 5 years was $20000.0 (2014), compared with a mean of $15470.6.
  • The widest YoY moves for Change in Accured Expenses: up 886.84% in 2017, down 9036.36% in 2017.
  • Eledon Pharmaceuticals' Change in Accured Expenses stood at -$464000.0 in 2013, then soared by 379.53% to $1.3 million in 2014, then increased by 9.87% to $1.4 million in 2015, then tumbled by 89.26% to $153000.0 in 2016, then tumbled by 727.45% to -$960000.0 in 2017.
  • The last three reported values for Change in Accured Expenses were -$960000.0 (Q4 2017), -$1.0 million (Q3 2017), and -$368000.0 (Q2 2017) per Business Quant data.